Category Archives: Ulcerative Colitis

AbbVie (ABBV) reported that it has received conditional approval in Europe for its proposed merger with Allergan (NYSE:AGN). Continue reading →

Further Strengthens Global Intellectual Property Portfolio for Tedopi in Immuno-Oncology Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnmo: OSE) (Paris:OSE) today announced that the Japanese Patent Office has issued a new patent family related to Tedopi, a combination of neoepitopes, protecting the products method for inducing early T-lymphocyte memory response for use in the treatment of cancer in HLA-A2 positive patients. This patent provides a protection until 2035. Tedopi is a combination of 10 neo-epitopes, selected and optimized from five tumor associated antigens inducing a specific immune response in positive HLA-A2 patients. Continue reading →

Lerner and Rowe Injury Attorneys LAS VEGAS (PRWEB) January 11, 2020 Lerner and Rowe Injury Attorneys is honored to pay tribute to the memory of Dana Marshall-Bernstein by supporting the Crohn's and Colitis Foundations inaugural Courage Ball. Continue reading →

A bureaucrat who said no to everything rarely got in trouble." - Tom Clancy, Executive Orders Today, we take a look at a small 'Tier 4' biotech concern that saw several insiders buy shares in December. The insider purchases immediately follow trial results that triggered a decent sell-off in the stock. The company has an early stage but a diverse and intriguing pipeline Continue reading →

The United Kingdoms Medicines and Healthcare products Regulatory Agency has approved the launch of Innovation Pharmaceuticals Phase 1 trial in healthy volunteers to investigate the safety and properties of delayed-release tablets of brilacidin for the treatment of ulcerative colitis (UC). Participant screening is expected to start in the coming weeks Continue reading →

Patients with underlying irritable bowel disease (IBD) have an increased risk of developing potentially severe gastrointestinal (GI) adverse events during immune checkpoint inhibitor therapy compared with patients without IBD, according to the results of an international, multicenter, retrospective study. The findings were published in the Journal of Clinical Oncology.1 The study included 102 retrospectively identified patients with IBD who were treated with an immune checkpoint inhibitor between January 2010 and February 2019 as a well as 11,377 patients without IBD to serve as a comparator group Continue reading →

The US House this morning passed the PFAS Action Act, 247-159, which would strengthen the nearly non-existent regulations for toxic perfluorinated compounds. Continue reading →

Tommy Joyce is no cinephile. Continue reading →

Innovation Wellness, located at 111 South Barron St., opened this past fall, ready to offer the community alternative solutions to their ailments. EATON Innovation Wellness, located at 111 South Barron St., opened this past fall, ready to offer the community alternative solutions to their ailments. Continue reading →

A fresh market research study titled Global Ulcerative Colitis Market explores several significant facets related to Ulcerative Colitis Market covering industry environment, segmentation analysis, and competitive landscape. Realistic concepts of the market are mentioned in a simple and plain manner in this report. A comprehensive and elaborate primary analysis report highlights numerous facts such as development factors, business enhancement strategies, statistical growth, financial gain or loss to help readers and clients to understand the market on a global scale Continue reading →